MMA Asset Management LLC Grows Stake in Pfizer Inc. $PFE

MMA Asset Management LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 27.3% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 26,757 shares of the biopharmaceutical company’s stock after acquiring an additional 5,744 shares during the quarter. MMA Asset Management LLC’s holdings in Pfizer were worth $649,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. SS&H Financial Advisors Inc. grew its stake in shares of Pfizer by 24.2% during the 2nd quarter. SS&H Financial Advisors Inc. now owns 80,407 shares of the biopharmaceutical company’s stock valued at $1,949,000 after purchasing an additional 15,668 shares during the period. Versor Investments LP boosted its holdings in shares of Pfizer by 561.8% in the second quarter. Versor Investments LP now owns 54,926 shares of the biopharmaceutical company’s stock worth $1,331,000 after buying an additional 46,626 shares during the last quarter. Plato Investment Management Ltd grew its position in Pfizer by 12.5% during the second quarter. Plato Investment Management Ltd now owns 212,518 shares of the biopharmaceutical company’s stock valued at $5,133,000 after buying an additional 23,646 shares during the period. Lifeworks Advisors LLC increased its holdings in Pfizer by 25.8% during the second quarter. Lifeworks Advisors LLC now owns 323,888 shares of the biopharmaceutical company’s stock valued at $7,851,000 after buying an additional 66,511 shares during the last quarter. Finally, Twin City Private Wealth LLC increased its holdings in Pfizer by 4.1% during the second quarter. Twin City Private Wealth LLC now owns 44,509 shares of the biopharmaceutical company’s stock valued at $1,079,000 after buying an additional 1,769 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

PFE has been the topic of several analyst reports. UBS Group reiterated a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Bank of America boosted their price target on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Citigroup raised their price objective on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $28.24.

Pfizer Stock Performance

NYSE:PFE opened at $24.68 on Monday. The stock has a 50-day moving average price of $24.77 and a 200 day moving average price of $24.30. The stock has a market capitalization of $140.29 billion, a P/E ratio of 13.13, a P/E/G ratio of 0.81 and a beta of 0.55. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $28.64. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the prior year, the company posted $0.60 EPS. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 7.0%. Pfizer’s payout ratio is presently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.